Search results
Showing 1 to 2 of 2 results for ta619
This guidance has been updated and replaced by NICE technology appraisal guidance 836.
Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.